The company will receive training, exclusive mentorship from industry experts, and access to a global network in addition to financial support
Flosonics Medical is pleased to announce that FloPatch was selected as a winner of Merck’s second annual Displaying Futures Award.
The Canadian medical device company was awarded $50,000 USD for the wireless, wearable Doppler ultrasound system that enables rapid, repeatable, and trusted hemodynamic assessments throughout the continuum of care.
In addition to financial support, Flosonics Medical will receive training, exclusive mentorship from industry experts, and access to a global network for a period of one year. The company will also attend a June 2018 event hosted by Merck KGaA where the management team will have the opportunity to pitch FloPatch technology to investors.
Flosonics Medical’s proprietary technology won the Displaying Futures Award alongside two other innovative technologies being developed in the United Kingdom and Canada. These technologies include Tangi0 and Texavie.
“We’re proud to have been selected by Merck for this prestigious award. We believe it is excellent validation for the broad clinical applications of our innovative technology,” said Joe Eibl, co-founder and CEO of Flosonics Medical.
Merck KGaA, a leading science and technology company based in Darmstadt, Germany, launched the annual Displaying Futures Award in 2016.
The company’s mission is to foster breakthrough innovations and support PhD candidates, post-docs, senior research scientists, and young entrepreneurs working on future-oriented business ideas.
This year’s call for proposals aimed to identify flexible applications in the field of hybrid electronics. The number of applications for the award program rose from 31 to 69 in 2017, submitted by creative minds from 22 countries around the world.
The ten best teams gathered for an event to pitch their ideas in Darmstadt on June 23, 2017. At the end of the event, a jury consisting of various Merck specialists chose three winning teams that were evaluated based on the criteria of novelty, business potential, and impacts on society and the environment.
Winning technologies included wearable biomonitoring devices, soft robotics, electronic sensors, and innovative packaging.
“We’re highly impressed by the second round of the award. “Both the multitude of submitted applications and the significant increase in quality confirm we’re on the right track. We’re also very proud of the wide range of topics that will involve all our business sectors and their expertise,” said Dieter Schroth, Senior Director of Liquid Crystals at Merck KGaA in Darmstadt, Germany.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck KGaA, Darmstadt, Germany, generated sales of €15.0 billion in 66 countries.
Founded in 1668, Merck KGaA, Darmstadt, Germany, is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck KGaA, Darmstadt, Germany, holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials. For more information, visit www.emdgroup.com.